The FDA elevated an experienced metabolic drug reviewer into a top CDER leadership role, naming Lisa Yanoff as acting deputy director. The appointment comes as the agency’s Center for Drug Evaluation and Research continues to manage high-volume review workloads and policy implementation across therapeutic areas. Yanoff is described as an agency veteran with expertise in metabolic drug reviews, and Acting FDA CDER director Michael Davis promoted her into the deputy role, according to the agency update. For drug developers in metabolic and cardiometabolic markets, the personnel change may influence how reviewer capacity is allocated among review divisions handling complex endpoints and safety considerations.